赛默飞专场:生物制药质谱解决方案

2017-08-22 赛默飞 赛默飞

《制药大咖说》以中国制药行业网上贸易平台“制药在线CPhI.cn”为后盾,以视频直播的方式,通过网络举办各类专业的在线讲座、产品推介会及主题研讨会,向10万制药专业人士传递企业声音、传播企业价值。

2017年8月10日,《制药大咖说》 “赛默飞专场”直播分享活动在CPhI直播室成功播出。

《制药大咖说》以中国制药行业网上贸易平台“制药在线CPhI.cn”为后盾,以视频直播的方式,通过网络举办各类专业的在线讲座、产品推介会及主题研讨会,向10万制药专业人士传递企业声音、传播企业价值。

赛默飞LCMS大分子应用工程师张晓夕
赛默飞LCMS大分子应用工程师张晓夕

本期《制药大咖说》携手全球科学服务领域的领导企业 -- 赛默飞世尔科技(中国)有限公司,分享更新更全的生物制药质谱解决方案。特邀赛默飞LCMS大分子应用工程师张晓夕担任演讲嘉宾。

张晓夕毕业于复旦大学,2012年加入赛默飞世尔公司,担任LCMS大分子应用工程师,负责LCMS在蛋白质组学、生物制药等大分子相关领域的售前及售后技术支持,实践经验丰富。近200名《制药大咖说》直播观众线上观看学习了张晓夕工程师分享的《基于静电场轨道阱 (Orbitrap) 质谱技术的生物制药解决方案》主题报告,热情参与了互动问答。

赛默飞静电场轨道阱 (Orbitrap) 作为蛋白质分析的领先技术,在生物制药领域有着广泛的应用,为不同的分析需求提供了强有力的数据支撑和规范化流程。静电场轨道阱是基于傅里叶变化原理的质量分析器,具有同时达到高灵敏度和高分辨率的硬件性能,适用于各种不同需求的分析目标。质谱性能的关键在于:准确度-Target、分辨率-Key、灵敏度-Basis。张晓夕老师通过仪器原理和常规分析流程出发,在线讲解了基于此质谱技术的生物制药解决方案,包括常规生物制药领域中的应用:完整分子量测定 -- ADC药物,完整蛋白分析,肽图分析(序列覆盖、糖肽分析、二硫键错配、各种翻译后修饰等),宿主细胞残留蛋白 (HCPs) 等。还分享了Thermo Scientific™ BioPharma Finder™ Software进行完整分子量测定的案例,可谓干货满满。

观众踊跃参与《制药大咖说》直播互动问答
观众踊跃参与《制药大咖说》直播互动问答

专业的分享获得了专业的业内观众首肯,直播互动氛围很好,观众听到精彩处时不时在线献花鼓掌表达感谢,到了互动提问环节,满屏的高质量提问基本上都得到了张晓夕老师耐心而专业的解答。直播的时间尽管有限,但学习交流的渠道是丰富的。直播结束后,那些没来得及被回答的问题,依然会由《制药大咖说》工作人员整理筛选后交给演讲嘉宾,在讲座结束后答复观众。想再回味一番的观众还可使用回放功能复习,体验超值。

质谱技术在有机分子的鉴定方面发挥着重要作用,随着质谱技术的发展,质谱技术的应用领域也越来越广,机器也越来越繁杂先进。及时更新行业知识,拉近空间距离高效与专业大咖深度交流,绝对获益匪浅。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987994, encodeId=cd06198e9942f, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 13 14:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237233, encodeId=677623e233cc, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Aug 26 07:05:27 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387645, encodeId=707d138e6453c, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465300, encodeId=da3114653001e, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553340, encodeId=346815533402c, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987994, encodeId=cd06198e9942f, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 13 14:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237233, encodeId=677623e233cc, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Aug 26 07:05:27 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387645, encodeId=707d138e6453c, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465300, encodeId=da3114653001e, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553340, encodeId=346815533402c, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-08-26 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1987994, encodeId=cd06198e9942f, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 13 14:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237233, encodeId=677623e233cc, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Aug 26 07:05:27 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387645, encodeId=707d138e6453c, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465300, encodeId=da3114653001e, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553340, encodeId=346815533402c, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987994, encodeId=cd06198e9942f, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 13 14:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237233, encodeId=677623e233cc, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Aug 26 07:05:27 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387645, encodeId=707d138e6453c, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465300, encodeId=da3114653001e, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553340, encodeId=346815533402c, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1987994, encodeId=cd06198e9942f, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Feb 13 14:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237233, encodeId=677623e233cc, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Aug 26 07:05:27 CST 2017, time=2017-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387645, encodeId=707d138e6453c, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465300, encodeId=da3114653001e, content=<a href='/topic/show?id=a74a926224b' target=_blank style='color:#2F92EE;'>#赛默飞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92622, encryptionId=a74a926224b, topicName=赛默飞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12366697882, createdName=yangwen5711, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553340, encodeId=346815533402c, content=<a href='/topic/show?id=81bd923e559' target=_blank style='color:#2F92EE;'>#质谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92375, encryptionId=81bd923e559, topicName=质谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96fd14366106, createdName=jeanqiuqiu, createdTime=Thu Aug 24 01:00:00 CST 2017, time=2017-08-24, status=1, ipAttribution=)]
    2017-08-24 jeanqiuqiu

相关资讯

“信心的力量”-- 抗乙肝病毒药物博路定在中国获批儿童适应症

基于国外已经完成的儿童适应症临床试验数据和中国进行的成人适应症长期临床观察数据,口服抗乙肝病毒药物博路定®(恩替卡韦片)于近日获得国家食品药品监督管理总局(CFDA)批准[1],用于治疗2岁至<18岁慢性乙肝病毒(HBV)感染代偿性肝病的核苷初治患者。